BioSpace News Archive

VolitionRX Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced today the pricing of its previously announced underwritten public offering of 3,500,000 shares of common stock at a public offering price of $2.40 per share.

AdvoCare International, L.P. today announced the promotion of Brett Blake to Chief Executive Officer, replacing industry-veteran Brian Connolly who served as interim-CEO during the extensive executive search.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has entered into definitive agreements with institutional investors to receive gross proceeds of approximately $5 million.

The Crohn’s & Colitis Foundation announced that John Crosson has been appointed Chair of its national Board of Trustees, and that five new trustees have been elected to the Board - Jason Burr, Joseph Monk, Cynthia Roth, Frank Russomano, and Jodi Yellen.

Exicure, Inc. reported full year financial results for the year ended December 31, 2017 and provided an update on corporate progress.

Study shows use of recAP results in greater than 40% relative reduction in mortality

Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the following upcoming conference

The U.S. Food and Drug Administration today issued warning letters to all three duodenoscope manufacturers for failing to comply with requirements of federal law under which they were ordered to conduct postmarket surveillance studies to assess the effectiveness of reprocessing the devices.

MiMedx Group Inc. announced that the U.S. Food and Drug Administration (FDA) has granted MiMedx’s micronized amniotic tissue, AmnioFix® Injectable, the Regenerative Medicine Advanced Therapy (RMAT) designation for use in the treatment of Osteoarthritis (OA) of the knee.

Humacyte announced that the company raised $75 million in a Series C preferred stock financing, led by a global consortium of existing private investors and new investors, including PointState Capital.